Table of Contents
- How Mold Damages the Lungs
- Hypersensitivity Pneumonitis (HP)
- Allergic Bronchopulmonary Aspergillosis (ABPA)
- Pulmonary Hemorrhage & Stachybotrys
- Chronic Pulmonary Aspergillosis (CPA)
- Mold-Triggered Asthma
- Fungal Rhinosinusitis and the Lower Respiratory Tract
- Pulmonary Conditions Comparison Table
- Getting Diagnosed
- Removing the Mold Source
How Mold Damages the Lungs
The human lung is the primary battleground when mold enters a living space. When airborne fungal spores are inhaled, they deposit on the mucociliary escalator of the upper airways, and the smallest particles — typically under 5 micrometers — penetrate deep into the alveolar sacs where gas exchange occurs. The immune response that follows can range from a transient allergic reaction to a life-altering interstitial lung disease, depending on the mold species, spore concentration, duration of exposure, and the individual's underlying health status.
Mold affects the lungs through three distinct biological mechanisms. First, living spores can colonize damaged or immunocompromised lung tissue, causing invasive or semi-invasive fungal infection. Second, fungal antigens trigger IgE-mediated hypersensitivity reactions and IgG-mediated immune complex deposition, provoking inflammatory cascades that destroy alveolar architecture. Third, mycotoxins — particularly trichothecenes produced by Stachybotrys chartarum — exert direct cytotoxic effects on pulmonary epithelium, hemorrhagic endothelium, and mucosal barriers, bypassing the immune system entirely.
Understanding which mechanism is at work is essential for both diagnosis and treatment. A patient suffering from Allergic Bronchopulmonary Aspergillosis requires antifungal therapy combined with corticosteroids; a patient with irritant-type asthma from volatile organic compounds (VOCs) released by mold colonies needs environmental remediation above all else. This guide walks through the full clinical spectrum of mold-related pulmonary disease.
For related reading, see our guides on mold and asthma, how mold suppresses the immune system, and fungal sinusitis and its pulmonary complications.
Hypersensitivity Pneumonitis (HP)
What Is Hypersensitivity Pneumonitis?
Hypersensitivity Pneumonitis (HP), also historically called Extrinsic Allergic Alveolitis, is a granulomatous interstitial lung disease driven by repeated inhalation of organic antigens. When the triggering antigen is Aspergillus fumigatus, thermophilic actinomycetes, or other fungi growing in water-damaged materials, the condition is sometimes grouped under the colloquial "Farmer's Lung" umbrella, though true Farmer's Lung specifically involves actinomycetes in moldy hay. Domestic HP from household mold is categorized as "Home HP" or "Domestic HP" and represents a growing proportion of diagnosed cases as building standards evolve.
The pathophysiology centers on lymphocytic alveolitis: CD4+ and CD8+ T-lymphocytes flood the alveolar interstitium in response to antigen re-exposure, producing a mixed Type III (immune complex) and Type IV (cell-mediated) hypersensitivity reaction. Granuloma formation follows, and in chronic cases the granulomas organize into fibrotic scar tissue that progressively reduces lung compliance and diffusing capacity. CT imaging characteristically shows ground-glass opacities, centrilobular nodules, and mosaic attenuation in acute and subacute phases, transitioning to upper-lobe predominant fibrosis with traction bronchiectasis in the chronic fibrotic stage — a pattern virtually indistinguishable from Usual Interstitial Pneumonia (UIP) or fibrotic Non-Specific Interstitial Pneumonia (NSIP).
Acute vs. Subacute vs. Chronic HP
Acute HP presents 4–8 hours after a high-intensity antigen exposure with fever, chills, myalgia, dry cough, and dyspnea that typically resolves within 24–72 hours of antigen removal. Recurrent acute episodes are commonly misdiagnosed as recurrent viral pneumonia or atypical bacterial infection. Subacute HP develops with lower-level but continuous exposure: progressive exertional dyspnea, productive cough, fatigue, and clubbing develop over weeks to months. Chronic HP involves irreversible fibrotic remodeling; lung function tests reveal a restrictive ventilatory defect (reduced TLC, FVC, and DLCO) that does not fully normalize even after antigen avoidance.
Early identification and removal from the mold environment is the single most critical intervention. Once fibrosis is established, antigen avoidance slows but does not reverse the loss of lung function. See our comprehensive mold and interstitial lung disease guide for deeper clinical detail.
Allergic Bronchopulmonary Aspergillosis (ABPA)
What Is ABPA?
Allergic Bronchopulmonary Aspergillosis is a complex hypersensitivity disorder caused specifically by colonization of the bronchial airways by Aspergillus fumigatus, typically occurring against a background of pre-existing asthma or cystic fibrosis. Unlike HP, which involves deep parenchymal inflammation, ABPA primarily damages the proximal and central airways, producing the pathognomonic finding of central bronchiectasis — permanent dilation of medium-sized airways — due to repeated cycles of mucus plugging, airway wall inflammation, and tissue destruction.
The immunological hallmark of ABPA is a markedly elevated total serum IgE, typically above 1,000 IU/mL (and often exceeding 10,000 IU/mL during exacerbations), along with elevated Aspergillus-specific IgE and IgG antibodies. Positive skin-prick reactivity to Aspergillus antigens completes the diagnostic triad. Peripheral blood eosinophilia (above 500 cells/μL) and characteristic "glove-finger" opacities on chest imaging — caused by impacted mucus in dilated bronchi — are additional diagnostic criteria.
ABPA Staging and Long-Term Prognosis
ABPA progresses through five stages: acute (Stage I), remission (Stage II), exacerbation (Stage III), corticosteroid-dependent asthma (Stage IV), and end-stage fibrosis with bronchiectasis and respiratory failure (Stage V). Patients cycle between stages II and III repeatedly unless antifungal therapy (typically itraconazole) is added to the corticosteroid regimen to reduce the fungal burden driving immune stimulation. Newer triazoles — voriconazole and posaconazole — are increasingly used when itraconazole bioavailability or drug interactions are a concern.
The environmental mold load matters greatly for ABPA management. Water-damaged homes, leaking HVAC systems, and damp basements harbor persistent Aspergillus reservoirs that continuously re-expose sensitized patients. Mold remediation combined with HEPA air filtration has been shown to reduce exacerbation frequency. Read our professional mold testing guide to understand how environmental sampling confirms the species responsible.
Pulmonary Hemorrhage and Stachybotrys chartarum
The Stachybotrys Controversy and Cleveland Infants
Stachybotrys chartarum, widely marketed under the name "black mold," produces a family of trichothecene mycotoxins — satratoxins, roridin E, and verrucarin J among them — that are potently cytotoxic to pulmonary vascular endothelium, alveolar macrophages, and mucosal epithelial cells. The primary route of concern is inhalation of spore-bound mycotoxin fragments from actively growing colonies on wet cellulose materials such as drywall, ceiling tiles, and paper-faced insulation.
The link between Stachybotrys and pulmonary hemorrhage in infants became the subject of intense scrutiny following a 1994 CDC investigation into a cluster of Idiopathic Pulmonary Hemorrhage (IPH) cases in Cleveland, Ohio. The cluster involved 10 infants living in water-damaged homes with documented Stachybotrys growth. While the CDC's initial 1997 report suggested an association, a subsequent 2000 re-analysis led by the CDC's own epidemiologists concluded the original methodology was flawed, and a definitive causal link was not established. The controversy has never been fully resolved: subsequent animal studies using direct intratracheal instillation of Stachybotrys spores in rats produced pulmonary hemorrhage, pulmonary inflammation, and trichothecene accumulation in lung tissue, providing biological plausibility that epidemiology alone could not confirm or refute.
Trichothecene Mechanisms of Pulmonary Injury
Trichothecenes inhibit eukaryotic protein synthesis by binding to the 60S ribosomal subunit. In pulmonary tissue, this translates to: disruption of alveolar capillary endothelial cell repair mechanisms, loss of tight junctions leading to vascular leak and hemorrhagic exudate, impairment of alveolar macrophage phagocytic activity, and suppression of mucociliary clearance. At concentrations achievable during high-intensity disturbance of heavily colonized drywall — during demolition or flooding remediation without proper containment — short-term exposures may be sufficient to trigger acute pulmonary injury in susceptible individuals.
Chronic Pulmonary Aspergillosis (CPA)
What Makes CPA Different from Invasive Aspergillosis
Chronic Pulmonary Aspergillosis encompasses a spectrum of non-invasive or semi-invasive Aspergillus-related pulmonary syndromes that develop in patients with pre-existing structural lung disease — most commonly prior tuberculosis or non-tuberculous mycobacterial infection, COPD with emphysematous bullae, sarcoidosis with cavitary lesions, prior pneumothorax, or previous lobectomy. Unlike Invasive Pulmonary Aspergillosis (IPA), which is an acute, rapidly progressive infection in severely immunocompromised hosts, CPA develops slowly over months to years in individuals who are not overtly immunocompromised but whose damaged lung architecture provides niches for Aspergillus colonization.
The hallmark CT finding of CPA is cavitary lung disease: pre-existing cavities expand, new satellite cavities form, and characteristic fungus balls (aspergillomas) — tangled masses of fungal hyphae, mucus, fibrin, and necrotic debris — form within cavities and produce the pathognomonic "air crescent sign" on CT as the fungus ball retracts from the cavity wall. Chronic cavitary pulmonary aspergillosis (CCPA), simple aspergilloma, and subacute invasive (formerly "semi-invasive") aspergillosis all fall within this spectrum.
Diagnosis and Treatment of CPA
Diagnosis requires elevated Aspergillus-specific IgG (precipitins), characteristic imaging findings, and exclusion of other diagnoses. Serum galactomannan and beta-D-glucan are less reliable in CPA than in IPA. Bronchoscopic lavage with culture and PCR is useful when the diagnosis is uncertain. Long-term oral voriconazole or itraconazole forms the backbone of treatment; surgical resection is reserved for simple aspergillomas in good surgical candidates or for life-threatening hemoptysis. Environmental mold reduction does not cure CPA but reduces the intensity of ongoing antigen exposure during treatment. Our mold and COPD guide details the intersection of obstructive lung disease and fungal colonization risk.
Mold-Triggered Asthma: Two Distinct Pathways
Mold triggers asthmatic responses through two fundamentally different mechanisms that require different management strategies. Distinguishing between them matters for both treatment and for understanding whether antifungal therapy or environmental remediation is the higher priority intervention.
IgE-mediated. The patient becomes sensitized to specific mold allergens (most commonly Alternaria alternata, Cladosporium herbarum, and Aspergillus fumigatus) through repeated exposure. Subsequent re-exposure triggers mast cell degranulation, eosinophilic airway inflammation, and bronchoconstriction. Total IgE and allergen-specific IgE testing are diagnostic. Immunotherapy (subcutaneous or sublingual) is an option for some patients. Environmental mold reduction dramatically reduces exacerbation frequency.
Non-IgE-mediated. Volatile organic compounds (VOCs) and mycotoxins released by actively growing mold colonies act as direct airway irritants, triggering neurogenic bronchoconstriction and non-specific airway hyperresponsiveness without classic IgE sensitization. RAST testing is negative. This pattern is more common in patients with higher-level, acute exposures. Standard IgE-based allergy testing misses this group, leading to misdiagnosis as "non-allergic asthma." Remediation of the mold source is the primary treatment.
Severe asthma with fungal sensitization (SAFS) is a recently recognized subset of difficult-to-control asthma in which sensitization to fungi — particularly Aspergillus and Alternaria — is present but the full ABPA diagnostic criteria are not met. Patients with SAFS frequently have high total IgE (100–1,000 IU/mL), demonstrate poor response to standard asthma therapy, and experience dramatic improvement when antifungal treatment is added. The distinction between SAFS and early ABPA is clinically challenging and often requires subspecialty pulmonology involvement. For further reading, see our mold and asthma guide and mold allergies guide.
Fungal Rhinosinusitis and the Lower Respiratory Tract
The upper and lower respiratory tracts form a unified airway, and fungal disease rarely respects anatomical boundaries. Fungal rhinosinusitis — whether allergic (AFRS) or chronic invasive — creates a persistent reservoir of fungal antigens and spores in the paranasal sinuses that continuously rains into the lower airways via mucociliary drainage and aspiration of mucus. Patients with allergic fungal rhinosinusitis (AFRS) are frequently sensitized to the same Aspergillus and Bipolaris species responsible for ABPA, and co-occurrence of both conditions in the same patient is well documented.
Post-nasal drip from fungal sinusitis irritates the laryngeal and tracheal mucosa, promoting cough-variant presentation that is easily misattributed to acid reflux or chronic bronchitis. More importantly, the chronic eosinophilic inflammation maintained by ongoing sinobronchial antigen load promotes bronchial hyperresponsiveness and accelerates the formation of central bronchiectasis in ABPA. ENT-pulmonology co-management is essential in patients where both diseases are present. Read more in our mold and sinuses guide and mold and headache guide.
Mold-Related Pulmonary Conditions: Comparison Table
The following table summarizes the eight most clinically significant mold-related pulmonary conditions, organized by mold species, pathogenic mechanism, diagnostic approach, symptom profile, at-risk populations, severity, and standard treatment. This table is intended as a clinical reference for patients, caregivers, and healthcare providers seeking to differentiate conditions that share overlapping presentations.
| Condition | Mold / Mycotoxin | Mechanism | Key Diagnostic Test | Symptoms | Population at Risk | Severity | Treatment |
|---|---|---|---|---|---|---|---|
| Hypersensitivity Pneumonitis (HP) | Aspergillus spp., thermophilic actinomycetes, Penicillium spp. | Mixed Type III / Type IV hypersensitivity; lymphocytic alveolitis, granuloma formation | HRCT (GGO, centrilobular nodules), BAL lymphocytosis >40%, serum precipitins | Dyspnea, dry cough, fever 4–8 hrs post-exposure; progressive exertional breathlessness in chronic form | Agricultural workers, water-damaged home occupants, immunocompetent adults | Moderate–Severe; can progress to irreversible pulmonary fibrosis | Antigen avoidance (primary); systemic corticosteroids; antifibrotic agents in fibrotic stage |
| Allergic Bronchopulmonary Aspergillosis (ABPA) | Aspergillus fumigatus | Type I (IgE) + Type III (IgG immune complex); bronchial hypersensitivity and eosinophilic inflammation | Total IgE >1,000 IU/mL; Aspergillus-specific IgE + IgG; central bronchiectasis on CT | Wheezing, productive cough, low-grade fever, brown mucus plugs, recurrent "pneumonia" | Asthma patients (1–2%), cystic fibrosis patients (up to 15%), corticosteroid-dependent asthmatics | Moderate–Severe; progressive central bronchiectasis and respiratory failure in Stage V | Oral corticosteroids + itraconazole or voriconazole; environmental remediation; biologics (dupilumab) emerging |
| Pulmonary Hemorrhage (Stachybotrys) | Stachybotrys chartarum; satratoxins, roridin E, verrucarin J | Direct mycotoxin cytotoxicity to vascular endothelium; disruption of alveolar capillary barrier; protein synthesis inhibition | BAL hemosiderin-laden macrophages; elevated trichothecene urine levels; environmental air sampling for Stachybotrys | Hemoptysis, recurrent pulmonary hemorrhage, feeding difficulties (infants), acute respiratory distress | Infants in water-damaged homes; construction/demolition workers disturbing contaminated drywall | Potentially life-threatening in infants; severe in high-exposure scenarios | Immediate removal from environment; supportive care; corticosteroids in acute hemorrhagic phase |
| Chronic Pulmonary Aspergillosis (CPA) | Aspergillus fumigatus, A. flavus | Colonization of pre-existing cavities; semi-invasive hyphal growth; progressive cavity expansion | Elevated Aspergillus IgG precipitins; CT showing cavities, aspergilloma, air crescent sign; BAL culture | Chronic cough, hemoptysis (often massive), weight loss, fatigue, progressive dyspnea | Prior TB, NTM, COPD with bullae, sarcoidosis, post-thoracic surgery patients | Severe; high mortality without treatment; massive hemoptysis risk | Long-term voriconazole or itraconazole (≥6 months); surgical resection for localized disease/hemoptysis |
| Mold-Triggered Asthma (Sensitization Type) | Alternaria alternata, Cladosporium spp., Aspergillus spp. | IgE-mediated Type I hypersensitivity; mast cell degranulation; eosinophilic airway inflammation | Elevated total IgE; positive allergen-specific IgE (RAST) or skin-prick test to mold extracts | Episodic wheezing, chest tightness, cough triggered by damp environments or high outdoor mold counts | Atopic individuals with pre-existing allergic disease; children; occupational exposure workers | Mild–Severe; risk of near-fatal asthma attacks with Alternaria sensitization during storm events | ICS + LABA; allergen immunotherapy; anti-IgE biologics (omalizumab); environmental mold control |
| Mold-Triggered Asthma (Irritant Type) | Volatile organic compounds (MVOCs) from multiple mold species; mycotoxin inhalation | Non-IgE neurogenic bronchoconstriction; direct airway epithelial irritation; tachykinin release | Methacholine challenge (bronchial hyperresponsiveness); negative IgE testing; environmental sampling showing elevated MVOC levels | Wheezing, cough, chest tightness in damp buildings; improvement away from building (sentinel symptom) | Occupants of water-damaged buildings; individuals with prior respiratory illness; no atopic predisposition required | Mild–Moderate; resolves with environmental remediation in most cases | Bronchodilators; ICS; primary intervention is mold source remediation and MVOC elimination |
| Fungal Pneumonia (Aspergillus) | Aspergillus fumigatus, A. terreus, A. flavus | Angio-invasive hyphal growth causing tissue infarction; vascular thrombosis; galactomannan release | Serum galactomannan index >0.5; beta-D-glucan; HRCT with halo sign or air crescent sign; BAL PCR | Fever refractory to antibiotics, hemoptysis, pleuritic chest pain, rapid respiratory deterioration | Severely immunocompromised: neutropenic, transplant recipients, high-dose steroid users, hematologic malignancy patients | Life-threatening; 30–90 day mortality 30–50% in high-risk populations without prompt treatment | Voriconazole (first-line); isavuconazole or liposomal amphotericin B (second-line); immunosuppression reduction |
| Mycotoxin-Induced DILI with Lung Involvement | Aflatoxins (Aspergillus flavus), trichothecenes (Stachybotrys), fumonisins (Fusarium) | Hepatotoxicity with secondary pulmonary hypertension; direct mycotoxin pulmonary vascular injury; immunosuppression enabling opportunistic infection | Elevated liver enzymes + elevated pulmonary artery pressure on echocardiography; mycotoxin assay in urine/serum; liver biopsy | Fatigue, jaundice, right upper quadrant pain + progressive dyspnea, edema, reduced exercise tolerance | Heavy occupational exposure; ingestion of contaminated food in conjunction with inhalation; hepatic comorbidities | Moderate–Severe; risk of combined hepatopulmonary syndrome and pulmonary hypertension | Mycotoxin source elimination; N-acetylcysteine; silymarin; pulmonary vasodilators for established PH; specialist co-management |
Table 1. Comparison of eight mold-related pulmonary conditions by mechanism, diagnosis, risk population, and treatment. ICS = inhaled corticosteroid; LABA = long-acting beta agonist; BAL = bronchoalveolar lavage; HRCT = high-resolution computed tomography; GGO = ground-glass opacity; NTM = non-tuberculous mycobacteria; IPA = invasive pulmonary aspergillosis.
Getting Diagnosed: What Tests to Request
Many patients with mold-related pulmonary disease spend months or years receiving empirical treatment for "asthma," "recurrent bronchitis," or "post-viral cough" before the fungal etiology is considered. The following diagnostic workup should be considered in any patient with chronic or recurrent respiratory symptoms and a history of residing or working in a water-damaged building:
- Total serum IgE: Markedly elevated (>1,000 IU/mL) in ABPA; moderately elevated in allergic mold asthma and SAFS.
- Aspergillus-specific IgE and IgG: Required for ABPA diagnosis; elevated IgG precipitins also seen in HP and CPA.
- Skin-prick testing to mold panels: Alternaria, Aspergillus, Cladosporium, Penicillium, and Helminthosporium at minimum.
- HRCT chest: Ground-glass opacities in HP, central bronchiectasis and mucus plugs in ABPA, cavitary lesions and aspergillomas in CPA, halo sign in IPA.
- Pulmonary function tests (spirometry + DLCO): Obstructive pattern in asthma/ABPA; restrictive pattern with reduced DLCO in HP.
- Bronchoalveolar lavage (BAL): BAL lymphocytosis >40% supports HP; eosinophilia supports ABPA; fungal culture and PCR for species identification.
- Serum galactomannan and beta-D-glucan: Useful for IPA in immunocompromised patients; less reliable in CPA.
- Methacholine challenge: Confirms bronchial hyperresponsiveness in mold-triggered asthma when spirometry is normal at rest.
Environmental testing is a critical complement to clinical testing. A professional mold air quality sample identifying Aspergillus or Stachybotrys colonies in the patient's home provides objective evidence that bridges the clinical diagnosis to the environmental exposure. See our guides on mold inspection, professional mold testing, and mold air sampling methods for a complete overview.
Removing the Mold Source: Why Medical Treatment Alone Is Not Enough
Every mold-related pulmonary condition described in this guide shares one common therapeutic requirement: elimination of the environmental mold source. Antifungal medications reduce fungal burden; corticosteroids suppress the immune response; bronchodilators relieve symptoms — but none of these treatments stop the cycle of re-sensitization and re-exposure as long as active mold colonies persist in the patient's living environment. This is why patients with ABPA who are treated pharmacologically but continue living in Aspergillus-contaminated homes cycle relentlessly through exacerbations without achieving durable remission.
Professional mold remediation involves more than surface cleaning. It requires physical containment of the work area to prevent spore dispersal, HEPA-filtered air scrubbing, removal and proper disposal of porous materials that cannot be cleaned (drywall, insulation, carpet), fungicidal treatment of salvageable hard surfaces, addressing the underlying moisture source driving mold growth, and post-remediation clearance testing confirming that airborne spore counts have returned to background levels. Our mold remediation process guide explains each phase of a compliant remediation project. See also our guides on what certifications matter for mold contractors and long-term mold prevention strategies.
Frequently Asked Questions
Can mold cause permanent lung damage?
Yes. Hypersensitivity Pneumonitis in its chronic fibrotic stage and ABPA in Stage V can both cause irreversible structural lung damage — pulmonary fibrosis and central bronchiectasis, respectively — that persists even after antigen avoidance. This is why early diagnosis and prompt mold source elimination are so important; the window for preventing permanent damage is finite. Patients who remove themselves from the mold environment early in the disease course have significantly better outcomes than those who continue exposure until symptoms become severe.
Which mold species are most dangerous for the lungs?
Aspergillus fumigatus is the single species responsible for the widest spectrum of serious lung disease: ABPA, CPA, Aspergillus-triggered HP, SAFS, and invasive pulmonary aspergillosis. Stachybotrys chartarum is the most toxicologically dangerous via mycotoxin production. Alternaria alternata is the species most strongly associated with near-fatal asthma attacks during high outdoor spore events. Cladosporium herbarum is the most common sensitizing mold in temperate climates. See our Aspergillus guide for detailed species information.
How long after mold removal do respiratory symptoms improve?
Response time varies by condition and duration of prior exposure. Irritant-type asthma often improves within days to weeks of environmental remediation. Sensitization-type allergic asthma typically shows improvement within 1–3 months as residual aeroallergen levels drop. ABPA exacerbation frequency decreases over 3–6 months with combined antifungal therapy and remediation. HP in its subacute stage often shows partial improvement in lung function within 3–6 months of antigen avoidance; fibrotic HP responds minimally to avoidance alone. Persistent symptoms beyond 3–6 months despite adequate remediation should prompt reassessment for ongoing exposure or concurrent diagnosis.
Should I leave my home during mold remediation?
For patients with diagnosed ABPA, HP, CPA, or significant sensitization-type asthma, temporary relocation during active remediation work is strongly recommended — particularly when containment barriers are being established or when large areas of contaminated material are being removed. Remediation disturbance dramatically elevates airborne spore counts within the work area, and even with proper containment, some spore migration into the living space can occur. Discuss specific guidance with both your treating pulmonologist and the remediation contractor before work begins.
This article is for informational purposes only and does not constitute medical advice. If you are experiencing respiratory symptoms, consult a qualified physician. For mold assessment and remediation services, contact Mold Remediation Hotline at (332) 220-0303.